Jacqueline Vuky

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

First-line Pembrolizumab, Urology, Metastatic Urothelial Cancer +7

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano et al. · Journal of Clinical Oncology · 2020 · 283 citations · Full text

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah, Philippe A. Cassier, Salvatore Siena et al. · Nature Medicine · 2022 · 224 citations · Full text

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky et al. · Journal of Clinical Oncology · 2022 · 175 citations

Androgen Receptor, Immunology, Protac Degrader +24